0000950170-23-064517.txt : 20231116
0000950170-23-064517.hdr.sgml : 20231116
20231116161514
ACCESSION NUMBER: 0000950170-23-064517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231114
FILED AS OF DATE: 20231116
DATE AS OF CHANGE: 20231116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COLES N ANTHONY
CENTRAL INDEX KEY: 0001197018
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 231414760
MAIL ADDRESS:
STREET 1: MORRIS CORP. CENTER I; BLDG. B; 4TH FLR.
STREET 2: 300 INTERPACE PARKWAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
ownership.xml
4
X0508
4
2023-11-14
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001197018
COLES N ANTHONY
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
true
false
false
false
false
Common Stock
2023-11-14
4
M
false
22824
3.50
A
25528
D
Common Stock
2023-11-14
4
S
false
22824
25.1251
D
2704
D
Stock Option (Right to Buy)
3.50
2023-11-14
4
M
false
22824
0
D
2028-12-24
Common Stock
22824
2502417
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.00 to $25.52. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option is fully vested and exercisable.
/s/ Mark Bodenrader, as Attorney-in-Fact
2023-11-16